Skip to main content

$0.850 0.030 (3.66%)

High

$0.99

Low

$0.84

Trades

317

Turnover

$865,876

Volume

942,590
30 June 2023 at 4:10pm
Register to track IIQ and receive email alerts.
Subject
IIQ Ann: Notification of cessation of securities - IIQ

IIQ Ann: SubB2M/CA15.3 Clinical Validation Data Investor Presentation

IIQ Ann: INOVIQ Investor Briefing

IIQ Ann: Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test

IIQ Ann: ISEV Meeting Presentations

IIQ Ann: Appendix 4C and Quarterly Activities Report - March 2023

IIQ Ann: INOVIQ to present new EXO-NET data at ISEV Annual Meeting

IIQ Ann: Change of Director's Interest Notice - Philip Powell

IIQ Ann: Change of Director's Interest Notice - Philip Powell

IIQ Ann: Appendix 4D and Half Year Financial Report

IIQ Ann: Positive results for SubB2M Breast Cancer Test

IIQ Ann: Notification regarding unquoted securities - IIQ

IIQ Ann: Notification of cessation of securities - IIQ

IIQ Ann: Appendix 4C & Quarterly Activities Report - December 2022

IIQ Ann: Final Director's Interest Notice

IIQ Ann: Resignation of Director

IIQ Ann: Positive EXO-NET Results in Ovarian Cancer

IIQ Ann: MST Access Diagnostics Forum Presentation

IIQ Ann: Change in substantial holding

IIQ Ann: Results of 2022 Annual General Meeting

IIQ Ann: CEO AGM Presentation

IIQ Ann: INOVIQ Settles Legal Proceedings

IIQ Ann: Commercial and R&D Update

IIQ Ann: Healthcare Conference Investor Presentation

IIQ Ann: Appendix 4C - Statement pursuant to Listing Rule 4.7C.3

IIQ Ann: IIQ Appendix 4C & Quarterly Activities Report-September 2022

IIQ Ann: Canadian Patent Granted for BARD1 Technology

IIQ Ann: Investor Presentation

IIQ Ann: Notice of Annual General Meeting

IIQ Ann: Receipt of R&D Tax Incentive Refund

IIQ Ann: INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform

IIQ Ann: Appendix 4G and Corporate Governance Statement

IIQ Ann: Appointment/Resignation of CFO and Company Secretary

IIQ Ann: Notification of cessation of securities - IIQ

IIQ Ann: Notice required under listing rule 3.13.1

IIQ Ann: 2022 Annual Report and update on results

IIQ Ann: Appendix 4E and Preliminary Financial Report

IIQ Ann: IIQ Investor Presentation

IIQ Ann: INOVIQ Investor Briefing Invitation - June 2022 Quarter

IIQ Ann: IIQ Appendix 4C & Quarterly Activities Report - June 2022

IIQ Ann: Positive SubB2M IHC Results for Melanoma

IIQ Ann: hTERT US Patent Granted

IIQ Ann: INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out

IIQ Ann: SubB2M US Patent Grant and Program Update

IIQ Ann: INOVIQ&University of Sydney Present New EXO-NET Data at ISEV

IIQ Ann: Change of Director's Interest - Philip Powell

IIQ Ann: IIQ Investor Presentation

IIQ Ann: Change of Director's Interest - Dr Geoffrey Cumming

IIQ Ann: Change of Director's Interest - Philip Powell

IIQ Ann: INOVIQ Investor Briefing Invitation

Register to track IIQ and receive email alerts.